A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

Running, not enrolling · Phase 1

Conditions studied: Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)

In brief

In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD. This study is designed to fulfill the long-term safety monitoring of EXG102-031. Participants that enroll in this long-term follow-up study have been treated with EXG102-031 under the main study (EXG102-031-211).

Key facts

Study ID

NCT06817343

Run by

Exegenesis Bio

People needed

12

Starts

2024-09-10

Expected to finish

2029-02-01

Last updated by the study team

2026-04-08

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have been previously enrolled in the parent study (EXG102-031-211) and must have received subretinal EXG102-031 in the parent study;
• Are willing and able to sign the study written informed consent form;
• Must be willing and able to comply with all study procedures.
• There are no exclusion Criteria in this study.

Where it is running

• Sierra Eye Associates — Reno, Nevada, United States
• Erie Retina Research — Erie, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.